Related Experiment Video
Updated: Nov 21, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.8K
Device-based treatment options for heart failure with preserved ejection fraction.
Chihiro Miyagi1, Takuma Miyamoto1, Jamshid H Karimov1
1Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Heart Failure Reviews
|January 12, 2021
Summary
Device-based therapies are emerging for heart failure with preserved ejection fraction (HFpEF). This review categorizes novel devices targeting pressure reduction to improve HFpEF patient outcomes.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge with limited effective treatments.
- Current pharmacological options for HFpEF are insufficient, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review and categorize emerging device-based therapies for HFpEF.
- To evaluate the potential of these devices in improving HFpEF patient prognosis and symptoms.
Main Methods:
- Categorization of device-based therapies into five groups: interatrial shunt devices, left ventricle expanders, electrical therapy, left ventricular assist devices, and developing mechanical circulatory support.
- Description of features, specifications, advantages, and limitations of each device category.
Main Results:
- Several device categories show promise for reducing left atrial pressure and pulmonary capillary wedge pressure in HFpEF.
- The review details devices in development and advanced preclinical stages, highlighting their unique mechanisms.
Conclusions:
- Device-based therapies represent a significant emerging area for HFpEF treatment.
- Further research into the safety and feasibility of these innovative technologies is crucial for clinical application in HFpEF patients.
Related Concept Videos
01:30Heart Failure V: Medical Management
93
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
93
01:22Heart Failure VI: Adjunct Therapies
109
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
109
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
672
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
672
01:30Heart Failure IV: Classification and Diagnostic Evaluation
135
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
135
01:30Cardiomyopathy II: Dilated Cardiomyopathy
152
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
152
01:29Cardiomyopathy V: Interprofessional Care
124
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
124